AssetMemo

Preview Research free. Sign in to unlock 3 full asset or company pages every day, no card needed.Sign in to unlock this page

Company profile

Verve Therapeutics

Subsidiary of Eli Lilly (LLY)

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
VERVE-102
Phase 2
PCSK9 gene (hepatocyte genomic DNA)Gene therapy / editing
Atherosclerotic Cardiovascular Disease
VERVE-201
Phase 1
ANGPTL3 gene (hepatocyte genomic DNA)Gene therapy / editing
Atherosclerotic Cardiovascular Disease

Upcoming events

Unlock with Research ↗
Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Unlock with Research ↗
Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share prices are end-of-day closes, delayed by 24 hours.